Impact of epidermal growth factor receptor (EGFR) mutations on responsiveness of non-small cell lung cancer (NSCLC) to tyrosine kinase inhibitors (TKIS): Prospective observations

被引：1
|
作者：
van Zandwijk, Nico
Mathy, Alexandre
de Jong, Daphne
Baas, Paul
Burgers, Sjaak
Nederlof, Petra
机构：
[1] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands
[2] Netherlands Canc Inst, Dept Mol Pathol, Amsterdam, Netherlands
来源：
EJC SUPPLEMENTS | 2006年 / 4卷 / 06期
关键词：
D O I：
10.1016/j.ejcsup.2006.04.030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
S29
引用
收藏
页码：14 / 15
页数：2
相关论文
共 50 条
  • [31] Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
    Hammerman, Peter S.
    Jaenne, Pasi A.
    Johnson, Bruce E.
    CLINICAL CANCER RESEARCH, 2009, 15 (24) : 7502 - 7509
  • [32] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer
    Ogunleye, Foluso
    Ibrahim, Mohammed
    Stender, Michael
    Kalemkerian, Gregory
    Jaiyesimi, Ishmael
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2015, 11 (01) : 16 - 25
  • [33] Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations
    Nishinarita, Noriko
    Igawa, Satoshi
    Kasajima, Masashi
    Kusuhara, Seiichiro
    Harada, Shinya
    Okuma, Yuriko
    Sugita, Keisuke
    Ozawa, Takahiro
    Fukui, Tomoya
    Mitsufuji, Hisashi
    Yokoba, Masanori
    Katagiri, Masato
    Kubota, Masaru
    Sasaki, Jiichiro
    Naoki, Katsuhiko
    ONCOLOGY, 2018, 95 (02) : 109 - 115
  • [34] Real world data on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) use in advanced/metastatic non-small cell lung cancer (NSCLC) with EGFR mutations in Singapore
    Chua, B.
    Tan, E. H.
    Lim, D. W-T.
    Ang, M-K.
    Tan, D. S. W.
    Ng, Q-S.
    Kanesvaran, R.
    Jain, A.
    Tan, W-L.
    Toh, C. K.
    Rajasekaran, T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [35] A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS (RCTS) ON EPIDERMAL GROWTH FACTOR RECEPTOR - TYROSINE KINASE INHIBITORS (EGFR-TKIS) FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Zhang, T.
    Xu, J.
    Ma, J.
    Cai, S.
    Wu, C.
    Liu, Y.
    VALUE IN HEALTH, 2014, 17 (03) : A68 - A68
  • [36] Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
    Jaenne, Pasi A.
    Johnson, Bruce E.
    CLINICAL CANCER RESEARCH, 2006, 12 (14) : 4416S - 4420S
  • [37] Rare and complex mutations of epidermal growth factor receptor (EGFR) and efficacy of tyrosine kinase inhibitor (TKI) in patients with non-small cell lung cancer (NSCLC).
    Keam, Bhumsuk
    Kim, Dong-Wan
    Park, Jin Hyun
    Lee, Jeong-Ok
    Kim, Tae Min
    Lee, Se-Hoon
    Jeon, Yoon-Kyung
    Chung, Doo Hyun
    Heo, Dae Seog
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC) A Systematic Review and Meta-analysis
    Raphael, Jacques
    Vincent, Mark
    Boldt, Gabriel
    Shah, Prakesh S.
    Rodrigues, George
    Blanchette, Phillip
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (05): : 440 - 445
  • [39] Impact of Local Therapy on Disease Progression and Survival Outcomes in Oligometastatic Epidermal Growth Factor Receptor (EGFR) Mutated Non-Small Cell Lung Cancer (NSCLC) Treated with First Line EGFR Tyrosine Kinase Inhibitors (Tkis)
    Soon, Y. Y.
    Lee, C. C.
    Koh, W. Y.
    Leong, C. N.
    Tey, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E152 - E152
  • [40] Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wildtype non-small cell lung cancer?
    Arriola, Edurne
    Taus, Alvaro
    Casadevall, David
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2015, 6 (04): : 45 - 56
12345